Tissue persistence of parvovirus B19 genotypes in asymptomatic persons
Fabiana Corcioli
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorKrystyna Zakrzewska
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorAlessio Rinieri
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorRosa Fanci
Department of Hematology, University of Firenze, Italy
Search for more papers by this authorMassimo Innocenti
Department of Orthopedics, Traumatology, Plastic Surgery and Rehabilitation, University of Firenze, Italy
Search for more papers by this authorRoberto Civinini
Department of Orthopedics, Traumatology, Plastic Surgery and Rehabilitation, University of Firenze, Italy
Search for more papers by this authorVincenzo De Giorgi
Department of Dermatological Sciences, University of Firenze, Italy
Search for more papers by this authorSimonetta Di Lollo
Department of Human Pathology, University of Firenze, Italy
Search for more papers by this authorCorresponding Author
Alberta Azzi
Department of Public Health, University of Firenze, Italy
Department of Public Health, University of Firenze, Viale Morgagni 48, 50134 Firenze Italy.===Search for more papers by this authorFabiana Corcioli
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorKrystyna Zakrzewska
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorAlessio Rinieri
Department of Public Health, University of Firenze, Italy
Search for more papers by this authorRosa Fanci
Department of Hematology, University of Firenze, Italy
Search for more papers by this authorMassimo Innocenti
Department of Orthopedics, Traumatology, Plastic Surgery and Rehabilitation, University of Firenze, Italy
Search for more papers by this authorRoberto Civinini
Department of Orthopedics, Traumatology, Plastic Surgery and Rehabilitation, University of Firenze, Italy
Search for more papers by this authorVincenzo De Giorgi
Department of Dermatological Sciences, University of Firenze, Italy
Search for more papers by this authorSimonetta Di Lollo
Department of Human Pathology, University of Firenze, Italy
Search for more papers by this authorCorresponding Author
Alberta Azzi
Department of Public Health, University of Firenze, Italy
Department of Public Health, University of Firenze, Viale Morgagni 48, 50134 Firenze Italy.===Search for more papers by this authorAbstract
Parvovirus B19 (B19V) can persist in immunocompetent symptomatic and non-symptomatic individuals, as demonstrated by the finding of viral DNA in different tissues, in absence of viremia and of anti-B19V IgM. The spread and the nature of this phenomenon have not been clearly determined. In order to investigate the frequency of persistence and the tissue distribution of the three genotypes of B19V, the viral load of the persistent virus and its expression in the affected tissues, 139 tissue samples and 102 sera from 139 asymptomatic individuals have been analyzed by consensus PCRs and genotype specific PCRs for B19V detection and genotyping. Viral load was measured by real time PCR and viral mRNAs were detected by RT-PCR. Altogether, 51% individuals carried B19V DNA, more frequently in solid tissues (65%) than in bone marrow (20%). Genotype 1 was found in 28% tissue samples, genotype 2 in 68% and genotype 3 in 3% only. Viral load ranged from less then 10 copies to 7 × 104 copies per 106 cells, with the exception of two samples of myocardium with about 106 copies per 106 cells. mRNA of capsid proteins was present in two bone marrow samples only. In conclusion, in asymptomatic individuals B19V persistence is more common in solid tissues than in bone marrow, and genotype 2 persists more frequently than genotype 1. The results suggest that the virus persists without replicating, at sub-immunogenic levels. J. Med. Virol. 80:2005–2011, 2008. © 2008 Wiley-Liss, Inc.
REFERENCES
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 102: 12891–12896.
- Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP, Pereira MS. 1983. Human Parvovirus, the cause of erythema infectiosum (fifth disease). Lancet 1: 1378.
- Baskan EB, Yilmaz E, Saricaoglu H, Alkan G, Ercan I, Mistik R, Adim SB, Goral G, Dilek K, Tunali S. 2007. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet's disease. Clin Exp Dermatol 32: 186–1190.
- Bauer HM, Ting YMS, Green CE, Chambers J, Tashiro C, Chimera J, Reingold A, Manos M. 1991. Genital human papillomavirus infection in female University students as determinated by a PCR-based method. JAMA 265: 472–477.
- Bostic JR, Brown KE, Young NS, Koenig S. 1999. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J. Infect Dis 179: 619–626.
- Broliden KT, Tolfvenstam T, Norbeck O. 2006. Clinical aspects of parvovirus B19 infection. J. Intern Med 260: 285–304.
- Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. 1984. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 2: 1033–1034.
- Candotti D, Etiz N, Parsyan A, Allain JP. 2004. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J. Virol 78: 12169–12178.
-
Cassinotti P,
Burtonboy G,
Fop M,
Siegl G.
1997.
Evidence for persistent of human parvovirus B19 DNA in bone marrow.
J. Med Virol
53:
229–232.
10.1002/(SICI)1096-9071(199711)53:3<229::AID-JMV8>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
-
Cassinotti P,
Siegl G,
Michel BA,
Bruhlmann P.
1998.
Presence and significance of human parvovirus B19 DNA in synovial menbranes and bone marrow from patients with arthritis of unknown origin.
J. Med Virol
56:
199–204.
10.1002/(SICI)1096-9071(199811)56:3<199::AID-JMV4>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, Söderlund-Venermo M. 2007. Biological and immunological relations among human parvovirus B19 genotypes 1 to 3. J. Virol 81: 6927–6935.
- Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. 2006. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 12: 151–154.
- Hemauer A, von Poblotzki A, Gigler A, Cassinotti G, Siegel G, Wolf H, Modrow S. 1996. Sequence variability among different parvovirus B19 isolates. J. Gen. Virol 77: 1781–1785.
- Hokynar K, Soderlund-Venermo M, Pesonen M, Ranki A, Kiviluoto O, Partio EK, Hedman K. 2002. A new parvovirus genotype persistent in human skin. Virology 302: 224–228.
- Johansen JN, Christensen LS, Zakrzewska K, Carlsen K, Hornsleth A, Azzi A. 1998. Typing of European strains of parvovirus B19 by restriction endonuclease analyses and sequencing: identification of evolutionary lineages and evidence of recombination of markers from different lineages. Virus Res 53: 215–223.
- Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. 2005. New DNA viruses identified in patients with acute viral infection syndrome. J. Virol 79: 8230–8236.
- Kerr JR. 2005. Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J. Vet Med B Infect Dis Vet Public Health 52: 335–339.
- Klein RM, Jiang H, Niederacher D, Adams O, Du M, Horlitz M, Schley P, Marx R, Lankisch MR, Brehm MU, Strauer BE, Gabbert HE, Scheffold T, Gülker H. 2004. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z. Kardiol 93: 300–309.
- Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. 2005. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111: 887–893.
- Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. 2008. Prevalence of Erythrovirus genotypes in the myocardium of patients with dilated cardiomyopahy. J. Med Virol 80: 1243–1251.
- Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Osaes R, Young NS. 1987. Chronic bone marrow failure due to persistent B19 parvovirus infection. N. Engl. J. Med 317: 287–294.
- Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. 2005. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106: 2890–2895.
- Lehmann HW, von Landenberg P, Modrow S. 2003. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2: 218–223.
- Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, Tolfvenstam T. 2005. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 41: 1201–1203.
- Lotze U, Egerer R, Tresselt C, Glück B, Dannberg G, Stelzner A, Figulla HR. 2004. Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med Microbiol Immunol 193: 75–82.
- Lundqvist A, Tolfvenstam T, Bostic J, Söderlund M, Broliden K. 1999. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 31: 11–16.
- Lundqvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. 1999a. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological desorders. Scand J Infect Dis 31: 119–122.
- Modrow S. 2006. Parvovirus B19: the causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard? Ernst Schering Res Found Workshop 55: 63–82.
- Musiani M, Zerbini M, Gentilomi G, Plazzi M, Gallinella G, Venturoli S. 1995. Parvovirus B19 clearance from peripheral blood after acute infection. J. Infect Dis 172: 1360–1363.
- Nguyen QT, Sifer C, Schneider V, Bernaudin F, Auguste V, Garbarg-Chenon A. 1998. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 352: 1524.
- Nguyen QT, Wong S, Heegaard ED, Brown KE. 2002. Identification and characterisation of a second novel human erythrovirus variant, A6. Virology 301: 374–3380.
- Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hubinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Soderlund-Venermo M, Hedman K. 2006. Bioportfolio: lifelong persistence of variant and prototypic eryth rovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 103: 7450–7453.
- Ohtsuka T, Yamazaki S. 2004. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150: 1091–1095.
- Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. 2003. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 34: 497–503.
- Poole BD, Zhou J, Grote A, Shiffenbauer A, Naides SJ. 2006. Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J. Virol 80: 4114–4121.
- Sanabani S, Neto WK, Pereira J, Sabino EC. 2006. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J. Clin Microbiol 44: 604–066.
- Schneider B, Höne A, Tolba RH, Fischer HP, Blümel J, Eis-Hübinger AM. 2008. Simultaneous persistence of multiple genome variants of human parvovirus B19. J. Gen Virol 89: 164–176.
- Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, Mohamed R. 1981. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 2: 595–597.
- Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. 2002. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol 76: 9124–9134.
- Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. 1997. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 349: 1063–1065.
- Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. 2002. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 50: 307–316.
- Tschöpe C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kühl U, Kandolf R, Schultheiss HP. 2005. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 111: 879–886.
- von Landenberg P, Lehmann HW, Modrow S. 2007. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 6: 278–285.
- Vuorinen T, Lammintausta K, Kotilainen P, Nikkari S. 2002. Presence of parvovirus B19 DNA in chronic urticaric and healthy human skin. Clin Virol 25: 217–221.
- Woolf AD. 1990. Human parvovirus B19 and arthritis. Behring Inst Mitt 85: 64–68.
- Young NS, Brown K. 2004. Parvovirus B19. N. Engl J Med 350: 586–597.
- Zakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, Tagariello G. 2001. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 65: 402–407.
Citing Literature
